Forendo Pharma completes €4M in funding from Vesalius and other existing investors.

Forendo Pharma, a Turku, Finland-based clinical stage drug development company focusing on novel treatments in women’s health, announced raising an additional €4M ($4.6M) of funding from Vesalius Biocapital Partners, through its fund, Vesalius III Partners.

This round is in addition to the €12M Series A financing from 2014 and €5,7M R&D loans granted by Business Finland since 2014.

Vesalius joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Novartis Venture Fund, M Ventures and Innovestor. In conjuction with the investment, Stéphane Verdood, Managing Partner from Vesalius III, joins Forendo Pharma’s Board of Directors.

The financing will enable Forendo Pharma to accelerate the development of its innovative women’s health portfolio.

Forendo Pharma, led by CEO Risto Lammintausta, is a drug development company with core competence in organ specific hormone mechanisms, giving new opportunities to unmet needs in women ́s and men ́s health.

Priro to this round, Forendo raised roughly $17M from outside investors.